July 2026 in “Skin Appendage Disorders” This review highlights that poor therapeutic responses in female pattern hair loss involve multiple factors, including pharmacogenetic influences and comorbidities. It suggests a framework to improve outcomes by identifying the primary contributors and using personalized treatment strategies.
1 citations
,
January 2010 This study in humans and pigs found that finasteride metabolism is significantly influenced by CYP3A4, with induced metabolism decreasing and inhibited metabolism increasing plasma exposure of the drug.
26 citations
,
June 2005 in “Journal of Molecular Endocrinology” This study found that both finasteride and dutasteride act as slow, time-dependent inhibitors of steroid 5α-reductase type II, with dutasteride being more efficient, influenced by the enzyme's genetic variants.
July 2026 in “Frontiers in Pharmacology” This study assessed pharmacogenomic variants and chemotherapy-related toxicity profiles in Tanzanian children with cancer, reporting notable genetic diversity that may influence toxicity but did not evaluate genotype-toxicity associations.
October 2024 in “Frontiers in Pharmacology” This study found that in patients with genetic generalized epilepsies, certain gene variants were linked to differences in valproic acid treatment outcomes, including a higher likelihood of treatment failure, varying serum drug concentrations, and specific side effects like weight gain and hair loss.